BridgeBio Submits NDA for Encaleret, Aims for 2027 Launch in ADH1

Event summary

  • BridgeBio submitted an NDA to the FDA for encaleret, a potential treatment for autosomal dominant hypocalcemia type 1 (ADH1).
  • Phase 3 CALIBRATE trial met all primary and key secondary endpoints, with 76% of participants achieving target calcium levels compared to 4% on conventional therapy.
  • BridgeBio anticipates a U.S. launch in early 2027 and plans to submit a Marketing Authorization Application (MAA) to the EMA in the second half of 2026.
  • The company also intends to initiate the RECLAIM-HP Phase 3 clinical study of encaleret in chronic hypoparathyroidism in Summer 2026.

The big picture

BridgeBio's submission of the NDA for encaleret marks a significant step in the development of a targeted therapy for ADH1, a rare genetic condition with limited treatment options. The positive Phase 3 trial results and anticipated regulatory submissions highlight the company's strategic focus on addressing unmet needs in genetic diseases. The potential approval of encaleret could position BridgeBio as a key player in the rare disease space, with implications for its market position and future growth.

What we're watching

Regulatory Pathway
Whether encaleret will receive priority review from the FDA and the timeline for potential approval.
Market Expansion
The pace at which BridgeBio can expand the potential applications of encaleret beyond ADH1, including chronic hypoparathyroidism.
Competitive Landscape
How encaleret's approval and launch will position BridgeBio in the rare disease treatment market.